Welcome to our dedicated page for Roivant Sciences Ltd. SEC filings (Ticker: ROIV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Roivant Sciences Ltd. filings document material events for a Nasdaq-listed Bermuda biopharmaceutical company with common shares registered under the ticker ROIV. The company’s recent Form 8-K disclosures cover quarterly financial results, preliminary liquidity information, share repurchases, Regulation FD updates and exhibits tied to clinical programs at subsidiaries such as Priovant Therapeutics.
Its filings also record material definitive agreements and amendments, including the Genevant Sciences settlement agreement involving lipid nanoparticle delivery technology, as well as shareholder voting results from the annual general meeting. Governance disclosures include director elections, auditor ratification and other proxy-related voting matters, while clinical exhibits describe programs such as brepocitinib in autoimmune and inflammatory diseases.
Roivant Sciences Ltd. (ROIV), through its consolidated affiliate Priovant, announces U.S. FDA approval and immediate commercial launch of LISRAYA (brepocitinib) as an oral TYK2/JAK1 inhibitor indicated for treatment of dermatomyositis in adult patients. The wholesale acquisition cost is $35,000 for a 30‑count bottle of 30 mg tablets, and a limited distribution specialty pharmacy network plus the My Compass Support hub are active, with eligible patients able to pay as little as $0 per month.
Approval is supported by the Phase 3 VALOR trial in 241 adults, where brepocitinib 30 mg showed a mean Total Improvement Score of 46.5 vs 31.2 for placebo and higher TIS40 and TIS60 response rates, along with meaningful steroid‑sparing effects. Literature and claims analyses suggest tens of thousands of potential U.S. dermatomyositis patients. Roivant owns 71% of Priovant (65% on a fully diluted basis) and consolidates 100% of Priovant’s revenues and expenses, with non‑controlling interest adjustments, and expects U.S. brepocitinib exclusivity at least until 2039.
Roivant Sciences Ltd. (ROIV) announced that the U.S. FDA has approved LISRAYA™ (brepocitinib) 30 mg, a once-daily oral pill, for the treatment of adults with dermatomyositis, based on data from its subsidiary Priovant Therapeutics’ Phase 3 VALOR trial, the largest dermatomyositis study conducted.
LISRAYA is described as a first-in-class TYK2/JAK1 inhibitor and the first and only targeted therapy approved for dermatomyositis. In VALOR, 55% of LISRAYA patients achieved moderate-or-better improvement on the myositis Total Improvement Score with minimal or no steroid use vs 30% on placebo over 52 weeks. Among those on ≥7.5 mg/day steroids at baseline, 62% tapered to ≤2.5 mg/day and 45% discontinued steroids entirely (vs 38% and 29% on placebo).
The approval follows FDA Priority Review and Orphan Drug Designation. LISRAYA carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis, and is not recommended in severe hepatic or renal impairment or in pregnancy. The drug is immediately available in the U.S. via specialty pharmacies, with a support program through which eligible patients may pay as little as $0 per month.
Roivant Sciences Ltd. (ROIV) reported that its CFO, Richard Pulik, had 5,749 Common Shares withheld on 2026-08-20 to satisfy tax withholding obligations upon the vesting and settlement of previously granted RSUs. This "net settlement" left him with 271,810 Common Shares held directly, including shares purchased under the company’s Employee Stock Purchase Plan.
Roivant Sciences Ltd. (ROIV) reported an insider equity event involving Eric Venker, President & Immunovant CEO. On 2026-08-20, 13,909 common shares were withheld in a code F transaction at $36.84 per share as a net settlement of RSUs to cover tax withholding upon vesting. Following this withholding, Venker’s directly held stake is reported as 1,599,154 common shares. This reflects tax-related share settlement rather than an open-market sale.
Roivant Sciences Ltd. (ROIV) reported that President & CIO Mayukh Sukhatme exercised stock options and sold the resulting common shares over three days. He exercised options covering 335,174 Common Shares at an exercise price of $3.85 per share, fully vested per the award footnote, and received an equal number of Common Shares. On August 19, 20 and 21, 2026, he sold 172,899, 17,519 and 144,756 Common Shares, respectively, at weighted average prices of $37.17, $37.30 and $36.48 per share in multiple transactions within the stated price ranges.
Roivant Sciences Ltd. (ROIV) is the issuer for a notice of proposed sale of common shares under Rule 144 filed on behalf of Mayukh Sukhatme. The planned sale involves common stock acquired through an Exercise of Options Under a Registered Plan, with Morgan Stanley Smith Barney LLC listed as the broker.
In addition to the proposed sale, the filing lists prior sales of Roivant common shares by Mayukh Sukhatme during the past three months, including multiple transactions in June and August 2026 with six-figure share amounts and eight-figure total dollar proceeds. The sales are to be executed for cash on the NASDAQ market.
Roivant Sciences Ltd. (symbol ROIV) received a notice that Mayukh Sukhatme plans to sell common shares under Rule 144. The notice covers a proposed sale of 17,519 shares, relating to an exercise of options under a registered plan, with prior substantial sales in the last three months.
Roivant Sciences Ltd. (ROIV) discloses that stockholder Mayukh Sukhatme has filed a notice under Rule 144 to sell 172,899 shares of Roivant common stock. The shares are to be sold on 08/19/2026 through Morgan Stanley Smith Barney LLC following an exercise of options under a registered plan.
The notice also lists prior sales of Roivant common stock by Sukhatme over the past three months, including individual transactions of 500,000 shares on both 06/25/2026 and 06/26/2026, and several additional sales in August 2026.
Roivant Sciences Ltd. (ROIV) reported that President & CIO Mayukh Sukhatme exercised stock options and sold common shares over three days. On August 14, 17, and 18, 2026, options with a $3.85 exercise price were exercised to acquire an aggregate of 664,826 common shares, which were then sold in multiple open-market transactions at weighted average prices reported as approximately $36.23, $36.25, $36.59, and $37.18 per share, with actual trade prices ranging from $36.10 to $37.30, as described in the footnotes.
Roivant Sciences Ltd. (ROIV) received a notice that Mayukh Sukhatme plans to sell common shares under Rule 144. The planned sale covers 136,942 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $5,029,208.64 as of the notice.
These shares are to be issued via exercise of options under a registered plan on 08/18/2026, with sales on NASDAQ. Roivant had 722,323,000 shares outstanding of this class. Over the past three months, Sukhatme reported several prior sales of Roivant common shares.